Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-isobutyl-1h-imidazo(4,5-c)quinolin-4-amine
2. Aldara
3. R 837
4. R-837
5. R837
6. S 26308
7. S-26308
8. Zyclara
1. 99011-02-6
2. Aldara
3. Zyclara
4. 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-amine
5. 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
6. Beselna
7. 4-amino-1-isobutyl-1h-imidazo[4,5-c]quinoline
8. R 837
9. 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
10. 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline
11. 9050-31-1
12. R-837
13. S-26308
14. C14h16n4
15. Mfcd00866946
16. Tmx-101
17. S26308
18. Nsc-369100
19. Nsc-759651
20. Chembl1282
21. 1-isobutylimidazo[4,5-c]quinolin-4-amine
22. P1qw714r7m
23. 1h-imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-
24. 1h-imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-
25. Chebi:36704
26. Ncgc00070736-02
27. Zartra
28. Imiquimod Acetate
29. Dsstox_cid_21047
30. Dsstox_rid_79617
31. Dsstox_gsid_41047
32. Aldara (tn)
33. Cas-99011-02-6
34. S 26308
35. Sr-01000611320
36. 1-(2-methylpropyl)-1h-imidazole[4,5-c]quinoline-4-amine
37. Unii-p1qw714r7m
38. Imiquimodum
39. Imiquimod [usan:inn:ban]
40. Vyloma
41. Mtd-39
42. Hsdb 8129
43. Tmx 101
44. Imiquimod,(s)
45. Imiquimod- Bio-x
46. 6t0
47. Imiquimod - Aldara
48. Zyclara (tn)
49. Dz-2636
50. R837
51. Imiquimod [inn]
52. Imiquimod [jan]
53. Imiquimod [mi]
54. Imiquimod [usan]
55. Imiquimod [vandf]
56. Imiquimod [mart.]
57. (non-labelled)imiquimod-d9
58. Imiquimod [usp-rs]
59. Imiquimod [who-dd]
60. Imiquimod (jan/usp/inn)
61. Schembl26136
62. Imiquimod [ema Epar]
63. Mls000083577
64. Bidd:gt0859
65. Gtpl5003
66. Imiquimod [orange Book]
67. Dtxsid7041047
68. Imiquimod [usp Monograph]
69. Hms2090m14
70. Hms2232g07
71. Hms3373b13
72. Hms3715n19
73. Hms3747a13
74. Pharmakon1600-01502351
75. Bcp05151
76. Hy-b0180
77. Tox21_110985
78. Ac-529
79. Bbl010772
80. Bdbm50240849
81. Nsc369100
82. Nsc759651
83. Nsc811538
84. S1211
85. Stk583860
86. Zinc19632912
87. Imiquimod - Cas 99011-02-6
88. Imiquimod, >=98% (hplc), Solid
89. Akos005507352
90. Cellulose, Hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl Methyl Ether
91. Tox21_110985_1
92. 1h-imidazo[4, 1-(2-methylpropyl)-
93. Ccg-208015
94. Cs-2058
95. Db00724
96. Ks-5218
97. Nsc 369100
98. Nsc 741062
99. Nsc 759651
100. Nsc-811538
101. Yh44175
102. (hydroxypropyl)methyl Cellulose Phthalate
103. Imiquimod 100 Microg/ml In Acetonitrile
104. Ncgc00070736-03
105. Ncgc00070736-04
106. Bi164576
107. Smr000048307
108. Sy017571
109. Ft-0602727
110. I0747
111. D02500
112. 1-isobutyl-1h-imidazo [4,5-c]quinolin-4-amine
113. 1-isobutyl-1h-imidazo[4,5-c]quinoline-4-amine
114. Ab00399298-05
115. Ab00399298-06
116. Ab00399298-07
117. Ab00399298_08
118. Ab00399298_09
119. 011i026
120. 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-ylamine
121. A845945
122. Q423417
123. 1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine
124. Sr-01000611320-2
125. Sr-01000611320-3
126. Brd-k26657438-001-01-2
127. Brd-k26657438-001-13-7
128. 1-(2-methylpropyl)-1himidazo[4,5-c]quinolin-4-amine
129. 1-(2-methylpropyl)-1h-imidazo[4,5-c]-quinolin-4-amine
130. Imiquimod, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 240.30 g/mol |
|---|---|
| Molecular Formula | C14H16N4 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 240.137496527 g/mol |
| Monoisotopic Mass | 240.137496527 g/mol |
| Topological Polar Surface Area | 56.7 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 294 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Aldara |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 5% |
| Market Status | Prescription |
| Company | Medicis |
| 2 of 6 | |
|---|---|
| Drug Name | Imiquimod |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 5% |
| Market Status | Prescription |
| Company | Apotex; Teva Pharms Usa; Taro; Strides Pharma; Glenmark Generics; Fougera Pharms; Tolmar; Perrigo Israel |
| 3 of 6 | |
|---|---|
| Drug Name | Zyclara |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | ZYCLARA (imiquimod) Cream, 2.5% or 3.75% is intended for topical administration. Each gram contains 25 mg or 37.5 mg of imiquimod, respectively, in a white to faintly yellow oil-in-water cream base consisting of isostearic acid, cetyl alcohol, steary... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | topical; Topical |
| Strength | 3.75%; 2.5% |
| Market Status | Prescription |
| Company | Medicis; Graceway |
| 4 of 6 | |
|---|---|
| Drug Name | Aldara |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 5% |
| Market Status | Prescription |
| Company | Medicis |
| 5 of 6 | |
|---|---|
| Drug Name | Imiquimod |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 5% |
| Market Status | Prescription |
| Company | Apotex; Teva Pharms Usa; Taro; Strides Pharma; Glenmark Generics; Fougera Pharms; Tolmar; Perrigo Israel |
| 6 of 6 | |
|---|---|
| Drug Name | Zyclara |
| PubMed Health | Imiquimod (On the skin) |
| Drug Classes | Immune Modulator |
| Drug Label | ZYCLARA (imiquimod) Cream, 2.5% or 3.75% is intended for topical administration. Each gram contains 25 mg or 37.5 mg of imiquimod, respectively, in a white to faintly yellow oil-in-water cream base consisting of isostearic acid, cetyl alcohol, steary... |
| Active Ingredient | Imiquimod |
| Dosage Form | Cream |
| Route | topical; Topical |
| Strength | 3.75%; 2.5% |
| Market Status | Prescription |
| Company | Medicis; Graceway |
Adjuvants, Immunologic; Antineoplastic Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 2013)
Imiquimod is used topically for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratosis on the face or scalp in immunocompetent adults; treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults; and treatment of external genital and perianal exophytic warts (condylomata acuminata) caused by human papillomavirus (HPV). /Included in US product label/
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3577
Topical imiquimod has been effective when used in a limited number of adults and children for the treatment of molluscum contagiosum. /NOT included in US product label/
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578
Imiquimod 5% cream has been used for the topical treatment of external genital and perianal HPV warts in a limited number of adults with human immunodeficiency virus (HIV) infection; however, the response rate appears to be lower in these individuals than in those who are not HIV infected. /NOT included in US product label/
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578
For more Therapeutic Uses (Complete) data for Imiquimod (6 total), please visit the HSDB record page.
Adverse local reactions, including erythema, erosion, excoriation/flaking, and edema, commonly occur at the site of application of imiquimod and/or surrounding areas. These reactions usually are mild to moderate in severity; however, severe local reactions have been reported.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578
In controlled studies in adults with actinic keratosis, the most frequently reported local skin reactions in those receiving imiquimod 5% cream (twice weekly for 16 weeks) were erythema (97%), flaking/scaling/dryness (93%), scabbing/crusting (79%), edema (49%), erosion/ulceration (48%), weeping/exudate (22%), and vesicles (9%).1 Application site reactions (e.g., bleeding, burning, induration, irritation, pain, pruritus, stinging, tenderness) occurred in 33% of those receiving topical imiquimod compared with 14% of those receiving placebo. In these studies, 16% of patients discontinued imiquimod treatment because of local or application site reactions and 91% of these were able to resume treatment after a rest period.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578
Adverse dermatologic reactions at sites away from the site of application have been reported in some patients receiving topical imiquimod. Remote site reactions have included bleeding, burning, edema, erosion, erythema, excoriation/flaking, induration, pain, pruritus, tenderness, tinea cruris, and ulceration.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3579
When imiquimod 5% cream was used in controlled studies in patients with genital and perianal HPV warts (3 times weekly for up to 16 weeks), erythema occurred in 58-65%, erosion in 30-31%, excoriation/flaking in 18-26%, edema in 12-18%, scabbing in 4-13%, induration in 5-7%, ulceration in 4-8%, and vesicles in 2-3% of those receiving the drug.1 In addition, application site reactions in those receiving the drug included pruritus (22-32%), burning (9-26%), pain (2-8%), and soreness (0-3%). In addition, fungal infections occurred in 2-11% of patients receiving the drug. Overall, 1.2% of patients in these studies discontinued treatment because of local or application site reactions.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3579
For more Drug Warnings (Complete) data for Imiquimod (25 total), please visit the HSDB record page.
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
FDA Label
Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
Imiquimod cream is indicated for the topical treatment of:
- external genital and perianal warts (condylomata acuminata) in adults;
- small superficial basal-cell carcinomas (sBCCs) in adults;
- clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and / or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs.
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Interferon Inducers
Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)
D06BB10
D06BB10
L03AX
D06BB10
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06B - Chemotherapeutics for topical use
D06BB - Antivirals
D06BB10 - Imiquimod
Absorption
Well absorbed through skin (as a cream)
Following topical application to the skin in adults with actinic keratosis (75-mg doses 3 times weekly for 16 weeks), 0.08-0.15% of the dose is eliminated in urine as unchanged drug and metabolites. Following topical application in patients with HPV warts, 0.11 or 2.41% of the dose is eliminated in urine as unchanged drug and metabolites in men or women, respectively.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580
Imiquimod is absorbed systemically following topical application to skin. In adults with actinic keratosis who received topical imiquimod 5% cream 3 times weekly for 16 weeks, mean peak serum concentrations at the end of week 16 were approximately 0.1, 0.2, or 3.5 ng/mL in those treated on the face (12.5-mg doses), scalp (25-mg doses), or hands/arms (75-mg doses), respectively. Systemic exposure appeared to depend more on the surface area of the application site than on the total applied dose. In patients with external genital and perianal human papillomavirus (HPV) warts who received topical imiquimod 5% cream (average dose 4.6 mg), mean peak serum concentrations were 0.4 ng/mL.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580
20 hours (topical dose), 2 hours (subcutaneous dose)
Studies using subcutaneous imiquimod indicate the drug has an apparent half-life of 2 hours. Following topical application, imiquimod appears to be retained in the skin for prolonged periods since the half-life is approximately 10 times greater than that reported following subcutaneous administration.
American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580
Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion.
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, /the researchers/ investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). /The researchers/ found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.
PMID:23402811 Jahnisch H et al; Cancer Lett. 2013 Feb 9 (Epub ahead of print)
Aldara is a cream used for topical treatment of non-melanoma skin cancer, and is thought to act through stimulation of anti-tumour immunity. The active ingredient, imiquimod, has been shown to stimulate toll-like receptor 7. Aldara also induces psoriasis-like lesions when applied to naive murine skin, and as such is used as a mouse model for psoriasis. Here we find that in naive murine skin, Aldara induces inflammation largely independently of toll-like receptor 7. Surprisingly, inflammasome activation, keratinocyte death and interleukin 1 release also occur in response to the vehicle cream in the absence of imiquimod. We show that isostearic acid, a major component of the vehicle, promotes inflammasome activation in cultured keratinocytes, and so may contribute to the observed effects of Aldara on murine skin. Aldara therefore stimulates at least two immune pathways independently, and both imiquimod and vehicle are required for a full inflammatory response. Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara.
PMID:23463003 Walter A et al; Nat Commun. 2013 Mar 5;4:1560
Imiquimod is recognized as an agonist for Toll-like receptor 7 (TLR7) in immunocompetent cells. TLR7, as well as TLR3 and TLR8, triggers the immune responses, such as the production of type I interferons (IFNs) and proinflammatory cytokines via recognition of viral nucleic acids in the infected cells. In this study, /the reseachers/ proposed that imiquimod has an IFN-independent antiviral effect in nonimmune cells. Imiquimod, but not resiquimod, suppressed replication of human herpes simplex virus 1 (HSV-1) in FL cells. We analyzed alternation of gene expression by treatment with imiquimod using microarray analysis. Neither type I IFNs, nor TLRs, nor IFN-inducible antiviral genes were induced in imiquimod-treated FL cells. Cystatin A, a host cysteine protease inhibitor, was strongly upregulated by imiquimod and took a major part in the anti-HSV-1 activity deduced by the suppression experiment using its small interfering RNA. Upregulation of cystatin A was suggested to be mediated by antagonizing adenosine receptor A(1) and activating the protein kinase A pathway. Imiquimod, but not resiquimod, was shown to interact with adenosine receptor A(1). Imiquimod-induced anti-HSV-1 activity was observed in other cells, such as HeLa, SiHa, and CaSki cells, in a manner consistent with the cystatin A induction by imiquimod. These results indicated that imiquimod acted as an antagonist for adenosine receptor A(1) and induced a host antiviral protein, cystatin A. The process occurred independently of TLR7 and type I IFNs.
PMID:22787201 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457300 Kan Y et al; J Virol 86 (19): 10338-46 (2012)
Toll-like receptor (TLR) agonists have anticancer effect by inducing apoptosis or activating immune cells. In this study, we investigated whether imiquimod, TLR7 agonist, inhibits the proliferation of oral cancer cells. Toll-like receptor 7 expression and IL-6/8 production by imiquimod were examined using RT-PCR and Enzyme-linked immunosorbent assay, respectively. Cell viability was examined by MTT assay. To examine apoptotic cell death, Annexin V/PI staining for flow cytometry and Western blot analysis were performed. Necrotic cell death was determined by leakage of lactate dehydrogenase (LDH), HMGB1, and PI staining in imiquimod-treated oral squamous cell carcinoma (OSCC) cells. Toll-like receptor 7 mRNA was expressed in OSCC cells. Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7. Imiquimod inhibited cells proliferation in a dose-dependent manner. The ratio of annexin V-positive cells and cleaved caspase-3/7 was increased by imiquimod treatment in OSCC cells, suggesting that imiquimod-induced cell death in OSCC cells may be owing to apoptosis. In addition, LDH secretion and PI staining were detected in OSCC cells treated with imiquimod, showing that imiquimod also induced necrotic cell death in the OSCC cells. Imiquimod inhibited effectively the growth of OSCC cells by inducing apoptosis and necrosis.
PMID:22577802 Ahn MY et al; J Oral Pathol Med 41 (7): 540-6 (2012)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease.
Lead Product(s): Zalifrelimab,Imiquimod
Therapeutic Area: Oncology Brand Name: UGN-301
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating lo...
Brand Name : UGN-301
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 01, 2022
Details:
The collaboration aims to advance combinatorial intravesical immunotherapy, UGN-201 (imiquimod), a TLR 7/8 agonist and UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, for the treatment of HG-NMIBC.
Lead Product(s): Zalifrelimab,Imiquimod
Therapeutic Area: Oncology Brand Name: UGN-301
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
UroGen And MD And erson Collaborate on Bladder Cancer Treatment Research
Details : The collaboration aims to advance combinatorial intravesical immunotherapy, UGN-201 (imiquimod), a TLR 7/8 agonist and UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, for the treatment of HG-NMIBC.
Brand Name : UGN-301
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 13, 2021
Details:
Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.
Lead Product(s): Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Lead Product(s) : Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
4-Chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quino...
CAS Number : 99010-64-7
End Use API : Imiquimod
About The Company : LUNA Chemicals Co.,Ltd. markets and manufactures world-class quality Active Pharmaceutical Ingredients and intermediate chemicals for generic pharmaceutical com...
CAS Number : 611-36-9
End Use API : Imiquimod
About The Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom sy...
CAS Number : 86-95-3
End Use API : Imiquimod
About The Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom sy...
3-Amino-4-isobutylamino quinoline
CAS Number : 99010-09-0
End Use API : Imiquimod
About The Company : “We, M/s.Trichem LifeSciences Limited believe that confidentiality and quality service is the key to maintaining customer relations. Keeping that in mind, the...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Packaging :
Approval Date : 2011-04-15
Application Number : 200173
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 3.75%
Packaging :
Approval Date : 2021-01-26
Application Number : 205971
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : TARO-IMIQUIMOD PUMP
Dosage Form : CREAM
Dosage Strength : 5%/W/W
Packaging :
Approval Date :
Application Number : 2482983
Regulatory Info : Prescription
Registration Country : Canada
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Packaging :
Approval Date : 2014-06-24
Application Number : 202002
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Australia
Brand Name : Aldiq
Dosage Form : cream
Dosage Strength : 5%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : APO-Imiquimod
Dosage Form : cream
Dosage Strength : 5%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : RX
Registration Country : USA
Brand Name : ZYCLARA
Dosage Form : CREAM;TOPICAL
Dosage Strength : 2.5%
Packaging :
Approval Date : 2011-07-15
Application Number : 22483
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Cream
Dosage Strength : 5%
Packaging : 0.25g
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Regulatory Info : DISCN
Registration Country : USA
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Packaging :
Approval Date : 2011-04-18
Application Number : 200481
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Cream
Dosage Strength : 3.75%
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : No
TE Code : AB
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Approval Date : 2011-04-15
Application Number : 200173
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 3.75%
Approval Date : 2021-01-26
Application Number : 205971
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
RLD : No
TE Code :
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Approval Date : 2014-06-24
Application Number : 202002
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Approval Date : 2012-04-06
Application Number : 91308
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
Brand Name : ALDARA
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1997-02-27
Application Number : 20723
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Brand Name : IMIQUIMOD
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Approval Date : 2010-02-25
Application Number : 78548
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Italy
Brand Name : IMMUNOCARE
Dosage Form : Cream
Dosage Strength : 0.05
Packaging : 12 UNITS 250 MG 5% - DERMATOLOGICAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : ALDARA
Dosage Form : Cream
Dosage Strength : 0.05
Packaging : 12 UNITS 250 MG 5% - DERMATOLOGICAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Aldara
Dosage Form : Cream
Dosage Strength : 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Zyclara
Dosage Form : Cream
Dosage Strength : 37.5mg/g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : ALDARA
Dosage Form : CREAM
Dosage Strength : 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Zyclara
Dosage Form : CREAM
Dosage Strength : 3.75%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Unocare
Dosage Form : Imiquimod 5% 250Mg 12 Units Cream Dermatological Use
Dosage Strength : cream derm 12 bust 250 mg 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Aldara Cream
Dosage Form : Imiquimod 5% 250Mg 12 Units Cream Dermatological Use
Dosage Strength : derm 12 sachets 250 mg 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Aldara
Dosage Form : Cream
Dosage Strength : 5%
Packaging : Disposable Bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Zyclara
Dosage Form : Cream
Dosage Strength : 3.75% w/w
Packaging : Disposable Bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Emulsifying Agents
Thickeners and Stabilizers
Parenteral
Surfactant & Foaming Agents
Rheology Modifiers
Granulation
Controlled & Modified Release
Direct Compression
Lubricants & Glidants
Coating Systems & Additives
API Stability Enhancers
Film Formers & Plasticizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
